14 completed, 3 active not recruiting, 1 terminated, 1 unknown. 9 Not applicable, 7 Phase 2, 3 Phase 1, 1 Phase 3, 1 Phase 4.
Follow Niagen: new trials by email Literature Review of Niagen trials Research Report on Niagen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nicotinamide Riboside Impact on Extracellular Nicotinamide Adenine Dinucleotide (NAD+) Niagen, Placebo - NAD | Not applicable | Unknown | Charite University, Berlin, Germany | 54 | 2023-11-01 | 2024-06-13 |
| N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease Nicotinamide Riboside, Placebo - Parkinson Disease | Phase 2 | Completed | Haukeland University Hospital | 81 | 2023-01-23 | 2025-07-08 |
| N-DOSE AD: A Dose Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease Placebo, Nicotinamide Riboside supplementation 1000mg daily in total, Nicotinamide Riboside dose escalation (up to 3000 mg daily in total) - Alzheimer Disease, Dementia | Phase 2 | Completed | Haukeland University Hospital | 80 | 2022-11-22 | 2025-12-01 |
| The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer Exercise Intervention, Nicotinamide Riboside - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Not applicable | Active not recruiting | City of Hope Medical Center | 20 | 2022-06-23 | 2026-10-23 |
| NR-SAFE: Safety of High-dose Nicotinamide Riboside (NR) in Parkinson's Disease Nicotinamide Riboside, Placebo - Parkinson Disease | Not applicable | Completed | Haukeland University Hospital | 20 | 2022-04-29 | 2022-08-09 |
| Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19 Niagen - Covid19, Sequelae of; Infection | Phase 4 | Completed | Massachusetts General Hospital | 72 | 2021-08-28 | 2025-08-05 |
| NR Supplementation and Exercise Niagen, Exercise - Overweight and Obesity, Aging | Not applicable | Completed | Maastricht University Medical Center | 30 | 2021-08-10 | 2023-02-10 |
| Nicotinamide Riboside in SARS-CoV-2 (COVID-19) Patients for Renal Protection Placebo, Nicotinamide riboside - SARS-CoV-2 Infection, Acute Kidney Injury | Phase 2 | Completed | The University of Texas Health Science Center at San Antonio | 28 | 2021-06-11 | 2023-12-26 |
| Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment Niagen, Placebo Comparator - Cognition Disorders in Old Age, Mild Cognitive Impairment | Not applicable | Completed | Steven E Arnold, MD | 61 | 2020-10-30 | 2024-11-29 |
| Pilot Study to Evaluate the Effect of Nicotinamide Riboside on Immune Activation in Psoriasis Niagen, Placebo - Psoriasis, Atherosclerotic Cardiovascular Disease | Not applicable | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 29 | 2020-08-26 | 2026-09-09 |
| NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy Nicotinamide riboside, Placebo capsules - Chemotherapy-induced Peripheral Neuropathy | Phase 2 | Active not recruiting | Donna Hammond, PhD | 48 | 2020-02-19 | 2026-08-20 |
| NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia Nicotinamide ribonucleoside - Ataxia Telangiectasia | Phase 2 | Active not recruiting | University Hospital, Akershus | 13 | 2019-06-05 | 2022-08-17 |
| Nicotinamide Riboside for Diabetic Neuropathy Niagen, Placebo - Diabetic Neuropathy Peripheral | Phase 1 / Phase 2 | Terminated | University of Maryland, Baltimore | 10 | 2019-01-24 | 2026-01-06 |
| Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease Nicotinamide riboside, Resveratrol, Placebo - Peripheral Artery Disease | Phase 3 | Completed | Northwestern University | 90 | 2018-10-01 | 2025-01-14 |
| Nicotinamide Riboside and Mitochondrial Biogenesis Nicotinamide Riboside - Mitochondrial Diseases, Mitochondrial Myopathies | Not applicable | Completed | Cambridge University Hospitals NHS Foundation Trust | 13 | 2017-12-08 | 2023-07-20 |
| Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes Nicotinamide Riboside, Matching placebo - Concussion, Mild | Not applicable | Completed | Mayo Clinic | 30 | 2016-09-01 | 2022-08-03 |
| Nicotinamide Riboside and Mitochondrial Metabolism NR in BMI-discordant twins, NR in BMI-concordant twins - Obesity | Not applicable | Completed | Helsinki University Central Hospital | 56 | 2016-05-25 | 2019-12-24 |
| Nicotinamide Riboside in Systolic Heart Failure nicotinamide riboside, Placebo - Heart Failure, Systolic | Phase 1 / Phase 2 | Completed | University of Washington | 30 | 2016-05-19 | 2022-11-16 |
| "Pharmacokinetic Study of Nicotinamide Riboside" nicotinamide riboside - Metabolic Disturbance | Phase 1 | Completed | University of Washington | 8 | 2015-11-01 | 2018-02-08 |
Obesity (3) · COVID-19 (2) · Mitochondrial Diseases (2) · Parkinson Disease (2) · Acute Kidney Injury (1) · Alzheimer Disease (1) · Ataxia Telangiectasia (1) · Atherosclerosis (1) · Brain Concussion (1) · Cognitive Dysfunction (1) · Dementia (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Dyslipidemias (1) · Heart Failure, Systolic (1)
Haukeland University Hospital (3) · University of Washington (2) · Cambridge University Hospitals NHS Foundation Trust (1) · Charite University, Berlin, Germany (1) · City of Hope Medical Center (1) · Donna Hammond, PhD (1) · Helsinki University Central Hospital (1) · Maastricht University Medical Center (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Northwestern University (1) · Steven E Arnold, MD (1) · The University of Texas Health Science Center at San Antonio (1) · University Hospital, Akershus (1)
United States (11) · Norway (4) · Germany (1) · Netherlands (1) · United Kingdom (1)
Kevin D O'Brien, MD (2) · Brent A Bauer, MD (1) · Charalampos Tzoulis, MD, PhD (1) · Charalampos Tzoulis, PhD (1) · Donna Hammond, Ph.D. (1) · Edmarie Guzman-Velez, PhD (1) · Hilde L Nilsen (1) · James W Russell, MD (1) · Kristoffer Haugarvoll, MD, PhD (1) · Kumar Sharma, MD (1) · Mary M McDermott, MD (1) · Michael Shy, M.D. (1) · Mohammed Milhem, M.D. (1) · Patrick Chinnery, Prof. (1)
PMID 29211728, PMID 36588397, PMID 36644285, PMID 38016950, PMID 41357333, PMID 42035974, PMID 42048163
R21HL126209 (2), 3UH3DK114920-04S2 (1), P30CA033572 (1)